
    
      The goal of this study is to obtain baseline information on serum and cerebrospinal fluid
      (CSF) relaxin and Sema4A levels in patients with MS, as well as to further study RXFP-1
      receptor binding affinity for RLX in patients with active and clinically stable MS, and
      further characterize the role of Sema4A in MS patients.
    
  